Consequently, TNF antagonists, e.g., etanercept, are clinically efficacious for the treatment of RA as they delay joint destruction via several mechanisms, such as decreasing cell recruitment to the inflamed joint [34,35] and synovial chemotactic cytokine expression [36]. This evidence concerns the gene TNF and rheumatoid arthritis.